Monument Tx has a well-balanced pipeline that includes two lead programmes with substantial central nervous system indications, each with a significant unmet medical need. Proprietary biomarkers developed by the Monument Tx team allows precise selection of the patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilising well-characterised actives in new therapeutic areas with improved efficacy and safety. The development plan for each programme permits rapid progress with early proof-of-concept data leading to Phase II clinical development.